F-star Therapeutics, Inc.
- Country
- π¬π§United Kingdom
- Ownership
- Public, Subsidiary
- Established
- 2006-01-01
- Employees
- 88
- Market Cap
- -
- Website
- http://www.f-star.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
- Conditions
- Hepatitis BHBVHepatitis B, Chronic
- Interventions
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04059198
- Locations
- ππ°
Queen Mary Hospital, Hong Kong, Hong Kong Island, Hong Kong
ππ°Prince of Wales Hospital, Sha Tin, New Territories, Hong Kong
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
- Conditions
- Hepatitis BHBVHepatitis B, Chronic
- Interventions
- Drug: Nucleoside/nucleotide (NUC) analogue inhibitors
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04023721
- Locations
- π¨π¦
University of Calgary, Calgary, Alberta, Canada
π¨π¦GI Research Institute, Vancouver, British Columbia, Canada
π¨π¦LAIR Centre, Vancouver, British Columbia, Canada
Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03932513
- Locations
- πΈπ¬
National University Hospital, Singapore, Singapore
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03493698
- Locations
- π³π±
University Medical Center Groningen, Groningen, Netherlands
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
- Conditions
- Hepatitis BHepatitis, Viral
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02751996
- Locations
- π°π·
Spring Bank Pharma Research site, Seoul, Korea, Republic of
π¨π³Spring Bank Pharma Research Site, Taoyuan County, Taiwan
π°π·Spring Pharma Research Site, Chuncheon-si, Gangwon-do, Korea, Republic of